This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)

Tipranks - Tipranks - Mon Jun 15, 3:56AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Palvella Therapeutics (PVLA) with bullish sentiments.

Claim 55% Off TipRanks

Biogen (BIIB)

Needham analyst Ami Fadia upgraded Biogen to Buy yesterday. The company’s shares closed last Friday at $200.05.

According to TipRanks.com, Fadia is a 5-star analyst with an average return of 29.7% and a 56.0% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, MapLight Therapeutics, Inc., and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $219.52 average price target, a 9.4% upside from current levels. In a report issued on June 12, Mizuho Securities also maintained a Buy rating on the stock with a $221.00 price target.

See the top stocks recommended by analysts >>

Palvella Therapeutics (PVLA)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Palvella Therapeutics on June 11 and set a price target of $270.00. The company’s shares closed last Friday at $108.81.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 20.8% and a 50.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and KalVista Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Palvella Therapeutics with a $234.89 average price target, representing an 119.9% upside. In a report issued on May 27, Mizuho Securities also reiterated a Buy rating on the stock with a $240.00 price target.

Read More on BIIB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).